Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City

Montag, 17.10.2016 14:05 von

PR Newswire

DUBLIN, Oct. 17, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has two presentations including a late breaking abstract that will be presented for the first time at the 72nd American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City, Utah, October 15-19.  

Logo -

The scheduled times (noted in local Mountain Daylight Time) of the presentations and room locations at the Salt Palace Convention Center are as follows:

  • "First US-Based Phase 3 Study of Ulipristal Acetate (UPA) for Symptomatic Uterine Fibroids (UF): Results of VENUS-I"
    • Presenter: James Simon
    • Program # O268, Late-breaking Abstract
    • Wednesday, October 19th,12 pm MT
  • "Clinical Performance of Diafert® to Determine Granulocyte Colony-Stimulating Factor (G-CSF) Concentration in Follicular Fluid (FF) as a Predictor of Implantation During In Vitro Fertilization (IVF)"
    • Presenter: Jean-Michel Foidart
    • Session # POO2, ART Outcome Predictors–Laboratory
    • Wednesday, October 19th, 7 am MT

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 15,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at                      

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.


Lisa DeFrancesco                                                                                        
(862) 261-7152

Mark Marmur
(862) 261-7558

Lisa Kim
(714) 246-3843

To view the original version on PR Newswire, visit:

SOURCE Allergan plc